Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

Video

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

In December 2018, olaparib (Lynparza) received regulatory approval as frontline maintenance therapy in patients with advanced ovarian cancer who harbor germline or somatic BRCA mutations. The decision is based on data from the phase III SOLO-1 trial, which showed a significant benefit in progression-free survival and time to first and second subsequent therapy or death with the agent versus placebo. Though data from the phase III PAOLA-1, PRIMA, and VELIA trials all showed a benefit with maintenance PARP inhibition in this setting, none of the other FDA-approved PARP inhibitors have received regulatory approval as frontline maintenance therapy, says Gunderson.

The benefit of PARP inhibition was observed in all-comers in these 3 trials, irrespective of homologous recombination deficiency (HRD) status or BRCA status, begging the question of whether bevacizumab (Avastin) or PARP maintenance should be used in patients with HRD defects or somatic BRCA mutations. The benefit of frontline PARP maintenance is clear in patients with germline BRCA mutations, says Gunderson. However, the benefit in all-comers will make patient selection more challenging, she concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,